65 related articles for article (PubMed ID: 19663652)
1. The effect of substituted thiophene and benzothiophene derivates on PPARgamma expression and glucose metabolism.
Shao H; Li D; Yang Y; Guo HF; Liu ZY; Si SY; Yang Z; Li ZR
J Enzyme Inhib Med Chem; 2010 Apr; 25(2):282-9. PubMed ID: 19663652
[TBL] [Abstract][Full Text] [Related]
2. Hypoglycemic action of thiazolidinediones/peroxisome proliferator-activated receptor gamma by inhibition of the c-Jun NH2-terminal kinase pathway.
Díaz-Delfín J; Morales M; Caelles C
Diabetes; 2007 Jul; 56(7):1865-71. PubMed ID: 17416798
[TBL] [Abstract][Full Text] [Related]
3. A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.
Chang CH; McNamara LA; Wu MS; Muise ES; Tan Y; Wood HB; Meinke PT; Thompson JR; Doebber TW; Berger JP; McCann ME
Eur J Pharmacol; 2008 Apr; 584(1):192-201. PubMed ID: 18346728
[TBL] [Abstract][Full Text] [Related]
4. PAR-1622 is a selective peroxisome proliferator-activated receptor gamma partial activator with preserved antidiabetic efficacy and broader safety profile for fluid retention.
Kim MK; Chae YN; Kim HS; Choi SH; Son MH; Kim SH; Kim JK; Moon HS; Park SK; Shin YA; Kim JG; Lee CH; Lim JI; Shin CY
Arch Pharm Res; 2009 May; 32(5):721-7. PubMed ID: 19471887
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological characteristics of a novel nonthiazolidinedione insulin sensitizer, FK614.
Minoura H; Takeshita S; Ita M; Hirosumi J; Mabuchi M; Kawamura I; Nakajima S; Nakayama O; Kayakiri H; Oku T; Ohkubo-Suzuki A; Fukagawa M; Kojo H; Hanioka K; Yamasaki N; Imoto T; Kobayashi Y; Mutoh S
Eur J Pharmacol; 2004 Jun; 494(2-3):273-81. PubMed ID: 15212984
[TBL] [Abstract][Full Text] [Related]
6. Molecular activation of PPARgamma by angiotensin II type 1-receptor antagonists.
Erbe DV; Gartrell K; Zhang YL; Suri V; Kirincich SJ; Will S; Perreault M; Wang S; Tobin JF
Vascul Pharmacol; 2006 Sep; 45(3):154-62. PubMed ID: 16765099
[TBL] [Abstract][Full Text] [Related]
7. 18F9 (4-(3,6-bis (ethoxycarbonyl)-4,5,6,7-tetrahydrothieno (2,3-c) pyridin-2-ylamino)-4-oxobutanoic acid) enhances insulin-mediated glucose uptake in vitro and exhibits antidiabetic activity in vivo in db/db mice.
Anandharajan R; Sayyed SG; Doshi LS; Dixit P; Chandak PG; Dixit AV; Brahma MK; Deshmukh NJ; Gupte R; Damre A; Suthar J; Padigaru M; Sharma SD; Nemmani KV
Metabolism; 2009 Oct; 58(10):1503-16. PubMed ID: 19608207
[TBL] [Abstract][Full Text] [Related]
8. Ertiprotafib improves glycemic control and lowers lipids via multiple mechanisms.
Erbe DV; Wang S; Zhang YL; Harding K; Kung L; Tam M; Stolz L; Xing Y; Furey S; Qadri A; Klaman LD; Tobin JF
Mol Pharmacol; 2005 Jan; 67(1):69-77. PubMed ID: 15475571
[TBL] [Abstract][Full Text] [Related]
9. The PPARgamma ligand, rosiglitazone, reduces vascular oxidative stress and NADPH oxidase expression in diabetic mice.
Hwang J; Kleinhenz DJ; Rupnow HL; Campbell AG; Thulé PM; Sutliff RL; Hart CM
Vascul Pharmacol; 2007 Jun; 46(6):456-62. PubMed ID: 17337254
[TBL] [Abstract][Full Text] [Related]
10. Muraglitazar, a novel dual (alpha/gamma) peroxisome proliferator-activated receptor activator, improves diabetes and other metabolic abnormalities and preserves beta-cell function in db/db mice.
Harrity T; Farrelly D; Tieman A; Chu C; Kunselman L; Gu L; Ponticiello R; Cap M; Qu F; Shao C; Wang W; Zhang H; Fenderson W; Chen S; Devasthale P; Jeon Y; Seethala R; Yang WP; Ren J; Zhou M; Ryono D; Biller S; Mookhtiar KA; Wetterau J; Gregg R; Cheng PT; Hariharan N
Diabetes; 2006 Jan; 55(1):240-8. PubMed ID: 16380499
[TBL] [Abstract][Full Text] [Related]
11. Anti-diabetic effects including diabetic nephropathy of anti-osteoporotic trace minerals on diabetic mice.
Maehira F; Ishimine N; Miyagi I; Eguchi Y; Shimada K; Kawaguchi D; Oshiro Y
Nutrition; 2011 Apr; 27(4):488-95. PubMed ID: 20708379
[TBL] [Abstract][Full Text] [Related]
12. Effect of GCP-02, a PPARalpha/gamma dual activator, on glucose and lipid metabolism in insulin-resistant mice.
Wang ZJ; Liu Q; Li PP; Zou CH; Shen ZF
Eur J Pharmacol; 2008 Feb; 580(1-2):277-83. PubMed ID: 18048028
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and anti-diabetic activity of (RS)-2-ethoxy-3-{4-[2-(4-trifluoro-methanesulfonyloxy-phenyl)-ethoxy]-phenyl}-propionic acid.
Cai ZF; Liu Q; Li PP; Guo ZR; Shen ZF
Acta Pharmacol Sin; 2006 May; 27(5):597-602. PubMed ID: 16626515
[TBL] [Abstract][Full Text] [Related]
14. S26948, a new specific peroxisome proliferator activated receptor gamma modulator improved in vivo hepatic insulin sensitivity in 48 h lipid infused rats.
Sohn KA; Cruciani-Guglielmacci C; Kassis N; Clément L; Ouali F; Caüzac M; Lebègue N; Berthelot P; Caignard DH; Pégorier JP; Renard P; Dacquet C; Ktorza A; Magnan C;
Eur J Pharmacol; 2009 Apr; 608(1-3):104-11. PubMed ID: 19250932
[TBL] [Abstract][Full Text] [Related]
15. Pan-PPAR agonist beneficial effects in overweight mice fed a high-fat high-sucrose diet.
Fernandes-Santos C; Carneiro RE; de Souza Mendonca L; Aguila MB; Mandarim-de-Lacerda CA
Nutrition; 2009; 25(7-8):818-27. PubMed ID: 19268533
[TBL] [Abstract][Full Text] [Related]
16. PAR-5359, a well-balanced PPARalpha/gamma dual agonist, exhibits equivalent antidiabetic and hypolipidemic activities in vitro and in vivo.
Kim MK; Chae YN; Son MH; Kim SH; Kim JK; Moon HS; Park CS; Bae MH; Kim E; Han T; Choi HH; Shin YA; Ahn BN; Lee CH; Lim JI; Shin CY
Eur J Pharmacol; 2008 Oct; 595(1-3):119-25. PubMed ID: 18727927
[TBL] [Abstract][Full Text] [Related]
17. Ameliorating effect of FK614, a novel nonthiazolidinedione peroxisome proliferator-activated receptor gamma agonist, on insulin resistance in Zucker fatty rat.
Minoura H; Takeshita S; Yamamoto T; Mabuchi M; Hirosumi J; Takakura S; Kawamura I; Seki J; Manda T; Ita M; Mutoh S
Eur J Pharmacol; 2005 Sep; 519(1-2):182-90. PubMed ID: 16039648
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of human insulin gene transcription by peroxisome proliferator-activated receptor gamma and thiazolidinedione oral antidiabetic drugs.
Schinner S; Krätzner R; Baun D; Dickel C; Blume R; Oetjen E
Br J Pharmacol; 2009 Jul; 157(5):736-45. PubMed ID: 19338578
[TBL] [Abstract][Full Text] [Related]
19. Antagonism of peroxisome proliferator-activated receptor gamma prevents high-fat diet-induced obesity in vivo.
Nakano R; Kurosaki E; Yoshida S; Yokono M; Shimaya A; Maruyama T; Shibasaki M
Biochem Pharmacol; 2006 Jun; 72(1):42-52. PubMed ID: 16696951
[TBL] [Abstract][Full Text] [Related]
20. Glutathione peroxidase 3 mediates the antioxidant effect of peroxisome proliferator-activated receptor gamma in human skeletal muscle cells.
Chung SS; Kim M; Youn BS; Lee NS; Park JW; Lee IK; Lee YS; Kim JB; Cho YM; Lee HK; Park KS
Mol Cell Biol; 2009 Jan; 29(1):20-30. PubMed ID: 18936159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
